Castle Biosciences Inc

CSTL remains in a Stage 2 advancing regime with intermediate uptrend intact. After a run into overbought territory near $35, price has retraced into the rising 9- and 20-day EMAs and is holding the $31.70–$33.20 support zone. This shallow pullback offers a tactical entry aligned with the Speculative strategy’s preference for continuation on momentum-based setups. Immediate participation on this support test targets the recent highs and beyond.

• ↑Q2 revenue reached $103.5M, +20% YoY driven by core tests
• ↑TissueCypher volumes rose 63% YoY to 14,988 reports
• ↓Net loss of $2.1M in Q2 2026 amid rising SG&A costs